ArticleDiabetes, obesity & metabolism2026
Electrospun Nanofiber Oral Thin Film Platform for Sublingual Peptide Delivery: A Promising Alternative to Conventional Semaglutide Formulations.
Article in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Electrospun Nanofiber Oral Thin Film Platform for Sublingual Peptide Delivery: A Promising Alternative to Conventional Semaglutide Formulations.Diabetes, obesity & metabolism · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundAdministration of drugs via the oromucosal route, especially using oral thin films, improves patient adherence compared to conventional oral and injectable methods. However, existing production techniques for oral thin films face considerable challenges in incorporating peptide and protein drugs. This study presents electrospun nanofiber-based oral thin film as a viable platform for the sublingual delivery of semaglutide. This platform was tested in Göttingen minipigs, which showed a greater response to attenuation of weight gain.
methodsSemaglutide-loaded InStrips were produced using electrospinning technology. Forty female, non-diabetic, non-obese Göttingen minipigs (6-7 months) were divided into groups based on sublingual (InStrip), peroral (Rybelsus), or subcutaneous (Ozempic) administration of semaglutide over 8 weeks, followed by a 1-week follow-up. InStrip formulations incorporated either sodium dodecyl sulphate (SDS) or sodium N-[8-(2-hydroxybenzoyl)amino] caprylate (SNAC) as permeation enhancers. Sublingual and peroral dosing occurred thrice weekly, whereas subcutaneous administration occurred once weekly.
resultsCompared to the placebo group, in over 9 weeks, InStrip administration resulted in attenuation in weight gain by 24.9%, surpassing that of the oral tablet (Rybelsus) group. Growth trajectory analysis showed statistically significant differences between the sublingual (InStrip) and placebo group (p = 0.013). In addition to superior weight management, InStrip semaglutide enhanced insulin and C-peptide levels.
conclusionSublingual delivery of semaglutide via InStrip enabled significant weight-modulating effects and improved biomarker responses compared to the placebo group. Despite limitations of a small study group and short duration, this study provides a strong foundation for further evaluation of InStrip as a viable delivery platform for semaglutide administration.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.